Health
STAT+: Invivyd’s pursuit of a Covid vaccine alternative gets a lift, but an FDA hurdle may await
Publication: STAT
Author: Adam Feuerstein
Source published: 01/10/2026, 10:30:00 UTC
Briefing created: 02/10/2026, 02:09:38 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 01/10/2026, 22:22:24 UTC.
Briefings
STAT+ reported on Tuesday, October 1, 2026, that biotech Invivyd's Phase 3 study LIBERTY showed VYD2311 had superior safety and tolerability compared to Pfizer's Comirnaty. The study found 57% of VYD2311 participants experienced injection site side effects versus 91% for Comirnaty, with the difference being statistically significant. Invivyd also noted VYD2311 could be safely combined with Comirnaty. This update follows a previous report in August 2025.
Key points
- Invivyd's Phase 3 study LIBERTY demonstrated VYD2311 had superior safety and tolerability compared to Comirnaty, with 57% of VYD2311 participants experiencing injection site side effects versus 91% for Comirnaty.
- The study showed VYD2311 could be safely combined with Comirnaty, and the difference in side effects was statistically significant.
Context and limitations
Data covers only the LIBERTY Phase 3 study results from six days and 56 days post-injection. The study is unapproved by the FDA, and the article does not provide details on long-term safety, efficacy outcomes, or regulatory approval timelines.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 02/10/2026, 02:09:38 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeidwvudc5mrcpfuy574wjjuhwefqp4gw6ur4zz2244szbhw55u2owm